Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

By sjmartinez • March 4, 2023

Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, Manning ME, Lumry WR, Saguer IM, Aygören-Pürsün E, Ritchie B, Sussman GL, Anderson J, Kawahata K, Suzuki Y, Staubach P, Treudler R, Feuersenger H, Glassman F, Jacobs I, Magerl M. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Feb 28:S0140-6736(23)00350-1. doi: 10.1016/S0140-6736(23)00350-1. Epub ahead of print. PMID: 36868261.

Tags: Allergy & Immunology, Publications

Chronic Nonallergic Rhinosinusitis Associated With Military Burn Pit Exposure

Lee YK, Tsai M, Anderson L, Wang V, Yusin J. Chronic Nonallergic Rhinosinusitis Associated With Military Burn Pit Exposure. Cureus. 2025 May 21;17(5):e84584. doi: 10.7759/cureus.84584.[...]

Nicolau syndrome: A case of ischemic necrosis after subcutaneous immunotherapy

Kim J, Kaddis T, Boyle S, Gupta S, Wang V, Yusin J. Nicolau syndrome: A case of ischemic necrosis after subcutaneous immunotherapy. J Allergy Clin Immunol[...]

Welcome New DoM Faculty

Jump To: CARDIOLOGY Omid Amidi, MD Doctor of Medicine:SUNY Downstate College of Medicine, Brooklyn, NY Residency: Baylor College of Medicine, Houston, TX Fellowship: University of[...]